Loading...

Daar, Eric S

Title(s)Professor of Clinical _____, Medicine
Phone(310) 222-2467
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Measuring and Monitoring Adherence to ART with Pill Ingestion Sensor System
    NIH/NIMH R01MH110056Sep 23, 2015 - Jul 31, 2020
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Liu H, Daar E, Wang Y, Siqueiros L, Campbell K, Shen J, Guerrero M, Ko MW, Xiong D, Dao J, Young T, Rosen M, Fletcher CV. Pharmacokinetics of Coencapsulated Antiretrovirals with Ingestible Sensors. AIDS Res Hum Retroviruses. 2020 Jan; 36(1):65-74. PMID: 31516025.
      View in: PubMed
    2. Daar ES, Rosen MI, Wang Y, Siqueiros L, Shen J, Guerrero M, Xiong D, Dao J, Young T, Corado K, Fletcher CV, Liu H. Real-Time and Wireless Assessment of Adherence to Antiretroviral Therapy With Co-Encapsulated Ingestion Sensor in HIV-Infected Patients: A Pilot Study. Clin Transl Sci. 2020 Jan; 13(1):189-194. PMID: 31536156.
      View in: PubMed
    3. Pan Y, Metsch LR, Gooden LK, Philbin MM, Daar ES, Douaihy A, Jacobs P, Del Rio C, Rodriguez AE, Feaster DJ. Viral suppression and HIV transmission behaviors among hospitalized patients living with HIV. Int J STD AIDS. 2019 08; 30(9):891-901. PMID: 31159715.
      View in: PubMed
    4. Hsue PY, Ribaudo HJ, Deeks SG, Bell T, Ridker PM, Fichtenbaum C, Daar ES, Havlir D, Yeh E, Tawakol A, Lederman M, Currier JS, Stein JH. Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314. Clin Infect Dis. 2019 05 17; 68(11):1877-1886. PMID: 30219823.
      View in: PubMed
    5. Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Acosta EP, Mager DE, Morse GD. Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202. Antimicrob Agents Chemother. 2019 04; 63(4). PMID: 30642925.
      View in: PubMed
    6. Hulgan T, Ramsey BS, Koethe JR, Samuels DC, Gerschenson M, Libutti DE, Sax PE, Daar ES, McComsey GA, Brown TT. Relationships Between Adipose Mitochondrial Function, Serum Adiponectin, and Insulin Resistance in Persons With HIV After 96 Weeks of Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2019 03 01; 80(3):358-366. PMID: 30531304.
      View in: PubMed
    7. Nir TM, Jahanshad N, Ching CRK, Cohen RA, Harezlak J, Schifitto G, Lam HY, Hua X, Zhong J, Zhu T, Taylor MJ, Campbell TB, Daar ES, Singer EJ, Alger JR, Thompson PM, Navia BA. Progressive brain atrophy in chronically infected and treated HIV+ individuals. J Neurovirol. 2019 Jun; 25(3):342-353. PMID: 30767174.
      View in: PubMed
    8. Milam J, Jain S, Dubé MP, Daar ES, Sun X, Corado K, Ellorin E, Blumenthal J, Haubrich R, Moore DJ, Morris SR. Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study Among Individuals at Risk of HIV. J Acquir Immune Defic Syndr. 2019 01 01; 80(1):e9-e13. PMID: 30334877.
      View in: PubMed
    9. Philbin MM, Feaster DJ, Gooden L, Duan R, Das M, Jacobs P, Lucas GM, Batey DS, Nijhawan A, Jacobson JM, Mandler R, Daar E, McMahon DK, Armstrong WS, Del Rio C, Metsch LR. The North-South Divide: Substance Use Risk, Care Engagement, and Viral Suppression Among Hospitalized Human Immunodeficiency Virus-Infected Patients in 11 US Cities. Clin Infect Dis. 2019 01 01; 68(1):146-149. PMID: 29920584.
      View in: PubMed
    10. Corado KC, Caplan MR, Daar ES. Two-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy. Drug Des Devel Ther. 2018; 12:3731-3740. PMID: 30464404.
      View in: PubMed
    11. Daar ES, Ruane P, DeJesus E, Stellbrink HJ, Molina JM. Antiretroviral switch studies do matter. Lancet HIV. 2018 10; 5(10):e546. PMID: 30319119.
      View in: PubMed
    12. Pasipanodya EC, Jain S, Sun X, Blumenthal J, Ellorin E, Corado K, Dube MP, Daar ES, Morris SR, Moore DJ. Trajectories and Predictors of Longitudinal Preexposure Prophylaxis Adherence Among Men Who Have Sex With Men. J Infect Dis. 2018 10 05; 218(10):1551-1559. PMID: 30295803.
      View in: PubMed
    13. Yang J, Nikanjam M, Best BM, Pinto J, Chadwick EG, Daar ES, Havens PL, Rakhmanina N, Capparelli EV. Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood. J Clin Pharmacol. 2018 12; 58(12):1604-1617. PMID: 30252146.
      View in: PubMed
    14. Kim J, De La Cruz J, Lam K, Ng H, Daar ES, Balamurugan A, Yang OO. CD8+ Cytotoxic T Lymphocyte Responses and Viral Epitope Escape in Acute HIV-1 Infection. Viral Immunol. 2018 09; 31(7):525-536. PMID: 30059271.
      View in: PubMed
    15. Haas DW, Bradford Y, Verma A, Verma SS, Eron JJ, Gulick RM, Riddler SA, Sax PE, Daar ES, Morse GD, Acosta EP, Ritchie MD. Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics. 2018 07; 28(7):179-187. PMID: 29847509.
      View in: PubMed
    16. Daar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C, Rockstroh JK, Molina JM, Koenig E, Liu YP, Custodio J, Andreatta K, Graham H, Cheng A, Martin H, Quirk E. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018 07; 5(7):e347-e356. PMID: 29925490.
      View in: PubMed
    17. Winhusen T, Feaster DJ, Duan R, Brown JL, Daar ES, Mandler R, Metsch LR. Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection. AIDS Behav. 2018 Jun; 22(6):2026-2032. PMID: 29030717.
      View in: PubMed
    18. Moore DJ, Jain S, Dubé MP, Daar ES, Sun X, Young J, Corado K, Ellorin E, Milam J, Collins D, Blumenthal J, Best BM, Anderson P, Haubrich R, Morris SR. Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study. Clin Infect Dis. 2018 05 02; 66(10):1566-1572. PMID: 29228144.
      View in: PubMed
    19. Caplan MR, Daar ES, Corado KC. Next generation fixed dose combination pharmacotherapies for treating HIV. Expert Opin Pharmacother. 2018 04; 19(6):589-596. PMID: 29557204.
      View in: PubMed
    20. Buchanan AL, Hudgens MG, Cole SR, Mollan KR, Sax PE, Daar ES, Adimora AA, Eron JJ, Mugavero MJ. Generalizing Evidence from Randomized Trials using Inverse Probability of Sampling Weights. J R Stat Soc Ser A Stat Soc. 2018 Oct; 181(4):1193-1209. PMID: 30555215.
      View in: PubMed
    21. Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Yang Y, Wilding GE, Morse GD. Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit. 2017 12; 39(6):596-603. PMID: 29135907.
      View in: PubMed
    22. Mollan KR, Tierney C, Hellwege JN, Eron JJ, Hudgens MG, Gulick RM, Haubrich R, Sax PE, Campbell TB, Daar ES, Robertson KR, Ventura D, Ma Q, Edwards DRV, Haas DW. Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants. J Infect Dis. 2017 09 01; 216(5):554-564. PMID: 28931220.
      View in: PubMed
    23. Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017 Nov 04; 390(10107):2063-2072. PMID: 28867497.
      View in: PubMed
    24. Wyles D, Bräu N, Kottilil S, Daar ES, Ruane P, Workowski K, Luetkemeyer A, Adeyemi O, Kim AY, Doehle B, Huang KC, Mogalian E, Osinusi A, McNally J, Brainard DM, McHutchison JG, Naggie S, Sulkowski M. Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. Clin Infect Dis. 2017 Jul 01; 65(1):6-12. PMID: 28369210.
      View in: PubMed
    25. Parker RA, Rabideau DJ, Sax PE, Tierney C, Daar ES, Collier AC, Losina E, Freedberg KA. Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study. Clin Infect Dis. 2017 Jun 01; 64(11):1612-1614. PMID: 28329243.
      View in: PubMed
    26. Raffi F, Orkin C, Clarke A, Slama L, Gallant J, Daar E, Henry K, Santana-Bagur J, Stein DK, Bellos N, Scarsella A, Yan M, Abram ME, Cheng A, Rhee MS. Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults. J Acquir Immune Defic Syndr. 2017 06 01; 75(2):226-231. PMID: 28272164.
      View in: PubMed
    27. Daar ES. Novel approaches to HIV therapy. F1000Res. 2017; 6:759. PMID: 28649373.
      View in: PubMed
    28. Verma A, Bradford Y, Verma SS, Pendergrass SA, Daar ES, Venuto C, Morse GD, Ritchie MD, Haas DW. Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics. 2017 03; 27(3):101-111. PMID: 28099408.
      View in: PubMed
    29. Corado KC, Daar ES. Emtricitabine + tenofovir alafenamide for the treatment of HIV. Expert Opin Pharmacother. 2017 Mar; 18(4):427-432. PMID: 28151023.
      View in: PubMed
    30. Karris MY, Jain S, Day TR, Pérez-Santiago J, Goicoechea M, Dubé MP, Sun X, Spina C, Daar ES, Haubrich RH, Morris S. HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen. HIV Clin Trials. 2017 03; 18(2):67-74. PMID: 28134057.
      View in: PubMed
    31. Metsch LR, Feaster DJ, Gooden L, Matheson T, Stitzer M, Das M, Jain MK, Rodriguez AE, Armstrong WS, Lucas GM, Nijhawan AE, Drainoni ML, Herrera P, Vergara-Rodriguez P, Jacobson JM, Mugavero MJ, Sullivan M, Daar ES, McMahon DK, Ferris DC, Lindblad R, VanVeldhuisen P, Oden N, Castellón PC, Tross S, Haynes LF, Douaihy A, Sorensen JL, Metzger DS, Mandler RN, Colfax GN, del Rio C. Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use: A Randomized Clinical Trial. JAMA. 2016 Jul 12; 316(2):156-70. PMID: 27404184.
      View in: PubMed
    32. Daar ES, Corado K. Condomless Sex With Virologically Suppressed HIV-Infected Individuals: How Safe Is It? JAMA. 2016 Jul 12; 316(2):149-51. PMID: 27404181.
      View in: PubMed
    33. Dan JM, Massanella M, Smith DM, Spina CA, Schrier R, Daar ES, Dube MP, Morris SR, Gianella S. Brief Report: Effect of CMV and HIV Transcription on CD57 and PD-1 T-Cell Expression During Suppressive ART. J Acquir Immune Defic Syndr. 2016 06 01; 72(2):133-7. PMID: 26818740.
      View in: PubMed
    34. Karris MY, Jain S, Bowman VQ, Rieg G, Goicoechea M, Dube MP, Kerkar S, Kemper C, Diamond C, Sun X, Daar ES, Haubrich RH, Morris S. Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue. J Acquir Immune Defic Syndr. 2016 06 01; 72(2):e48-50. PMID: 26977746.
      View in: PubMed
    35. Milam J, Morris S, Jain S, Sun X, Dubé MP, Daar ES, Jimenez G, Haubrich R. Randomized Controlled Trial of an Internet Application to Reduce HIV Transmission Behavior Among HIV Infected Men Who have Sex with Men. AIDS Behav. 2016 06; 20(6):1173-1181. PMID: 26487300.
      View in: PubMed
    36. Borges ÁH, Lundh A, Tendal B, Bartlett JA, Clumeck N, Costagliola D, Daar ES, Echeverría P, Gisslén M, Huedo-Medina TB, Hughes MD, Huppler Hullsiek K, Khabo P, Komati S, Kumar P, Lockman S, MacArthur RD, Maggiolo F, Matteelli A, Miro JM, Oka S, Petoumenos K, Puls RL, Riddler SA, Sax PE, Sierra-Madero J, Torti C, Lundgren JD. Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials. Clin Infect Dis. 2016 07 15; 63(2):268-80. PMID: 27090986.
      View in: PubMed
    37. Gallant JE, Daar ES, Raffi F, Brinson C, Ruane P, DeJesus E, Johnson M, Clumeck N, Osiyemi O, Ward D, Morales-Ramirez J, Yan M, Abram ME, Plummer A, Cheng AK, Rhee MS. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016 Apr; 3(4):e158-65. PMID: 27036991.
      View in: PubMed
    38. Wohl AR, Dierst-Davies R, Victoroff A, James S, Bendetson J, Bailey J, Daar E, Spencer L, Kulkarni S, Pérez MJ. Implementation and Operational Research: The Navigation Program: An Intervention to Reengage Lost Patients at 7 HIV Clinics in Los Angeles County, 2012-2014. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):e44-50. PMID: 26484741.
      View in: PubMed
    39. Gianella S, Ginocchio CC, Daar ES, Dube MP, Morris SR. Genital Epstein Barr Virus is associated with higher prevalence and persistence of anal human papillomavirus in HIV-infected men on antiretroviral therapy. BMC Infect Dis. 2016 Jan 25; 16:24. PMID: 26809559.
      View in: PubMed
    40. Vanpouille C, Introini A, Morris SR, Margolis L, Daar ES, Dube MP, Little SJ, Smith DM, Lisco A, Gianella S. Distinct cytokine/chemokine network in semen and blood characterize different stages of HIV infection. AIDS. 2016 Jan; 30(2):193-201. PMID: 26558730.
      View in: PubMed
    41. Wanga V, Venuto C, Morse GD, Acosta EP, Daar ES, Haas DW, Li C, Shepherd BE. Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics. 2015 Sep; 25(9):450-61. PMID: 26148204.
      View in: PubMed
    42. Massanella M, Gianella S, Schrier R, Dan JM, Pérez-Santiago J, Oliveira MF, Richman DD, Little SJ, Benson CA, Daar ES, Dube MP, Haubrich RH, Smith DM, Morris SR. Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy. Sci Rep. 2015 Aug 24; 5:13179. PMID: 26299251.
      View in: PubMed
    43. Gianella S, Smith DM, Daar ES, Dube MP, Lisco A, Vanpouille C, Margolis L, Haubrich RH, Morris SR. Genital Cytomegalovirus Replication Predicts Syphilis Acquisition among HIV-1 Infected Men Who Have Sex with Men. PLoS One. 2015; 10(6):e0130410. PMID: 26061824.
      View in: PubMed
    44. Longenecker CT, Kitch D, Sax PE, Daar ES, Tierney C, Gupta SK, McComsey GA. Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s. J Acquir Immune Defic Syndr. 2015 Jun 01; 69(2):168-77. PMID: 26009829.
      View in: PubMed
    45. Moore BA, Rosen MI, Wang Y, Shen J, Ablondi K, Sullivan A, Guerrero M, Siqueiros L, Daar ES, Liu H. A Remotely-Delivered CBT and Contingency Management Therapy for Substance Using People with HIV. AIDS Behav. 2015 Jun; 19 Suppl 2:156-62. PMID: 25645326.
      View in: PubMed
    46. Anderson AM, Harezlak J, Bharti A, Mi D, Taylor MJ, Daar ES, Schifitto G, Zhong J, Alger JR, Brown MS, Singer EJ, Campbell TB, McMahon DD, Buchthal S, Cohen R, Yiannoutsos C, Letendre SL, Navia BA. Plasma and Cerebrospinal Fluid Biomarkers Predict Cerebral Injury in HIV-Infected Individuals on Stable Combination Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2015 May 01; 69(1):29-35. PMID: 25622053.
      View in: PubMed
    47. Lehmann DS, Ribaudo HJ, Daar ES, Gulick RM, Haubrich RH, Robbins GK, de Bakker PI, Haas DW, McLaren PJ. Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics. 2015 Feb; 25(2):51-9. PMID: 25461247.
      View in: PubMed
    48. Wyatt CM, Kitch D, Gupta SK, Tierney C, Daar ES, Sax PE, Ha B, Melbourne K, McComsey GA. Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine. J Acquir Immune Defic Syndr. 2014 Sep 01; 67(1):36-44. PMID: 25117929.
      View in: PubMed
    49. Venuto CS, Mollan K, Ma Q, Daar ES, Sax PE, Fischl M, Collier AC, Smith KY, Tierney C, Morse GD. Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202. J Antimicrob Chemother. 2014 Dec; 69(12):3300-10. PMID: 25159623.
      View in: PubMed
    50. Al-Mawsawi LQ, Wu NC, De La Cruz J, Shi VC, Wu TT, Daar ES, Lewis MJ, Yang OO, Sun R. Short communication: HIV-1 gag genetic variation in a single acutely infected participant defined by high-resolution deep sequencing. AIDS Res Hum Retroviruses. 2014 Aug; 30(8):806-11. PMID: 24914638.
      View in: PubMed
    51. Calvo KR, Daar ES. Antiretroviral therapy: treatment-experienced individuals. Infect Dis Clin North Am. 2014 Sep; 28(3):439-56. PMID: 25151565.
      View in: PubMed
    52. Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, Gulick RM, Na L, O'Keefe L, Robertson KR, Tierney C. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med. 2014 Jul 01; 161(1):1-10. PMID: 24979445.
      View in: PubMed
    53. Kuang XT, Li X, Anmole G, Mwimanzi P, Shahid A, Le AQ, Chong L, Qian H, Miura T, Markle T, Baraki B, Connick E, Daar ES, Jessen H, Kelleher AD, Little S, Markowitz M, Pereyra F, Rosenberg ES, Walker BD, Ueno T, Brumme ZL, Brockman MA. Impaired Nef function is associated with early control of HIV-1 viremia. J Virol. 2014 Sep 01; 88(17):10200-13. PMID: 24965469.
      View in: PubMed
    54. Erlandson KM, Kitch D, Tierney C, Sax PE, Daar ES, Melbourne KM, Ha B, McComsey GA. Impact of randomized antiretroviral therapy initiation on glucose metabolism. AIDS. 2014 Jun 19; 28(10):1451-61. PMID: 24637543.
      View in: PubMed
    55. Zheng Y, Hughes MD, Lockman S, Benson CA, Hosseinipour MC, Campbell TB, Gulick RM, Daar ES, Sax PE, Riddler SA, Haubrich R, Salata RA, Currier JS. Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens. Clin Infect Dis. 2014 Sep 15; 59(6):888-96. PMID: 24842909.
      View in: PubMed
    56. Gianella S, Massanella M, Richman DD, Little SJ, Spina CA, Vargas MV, Lada SM, Daar ES, Dube MP, Haubrich RH, Morris SR, Smith DM. Cytomegalovirus replication in semen is associated with higher levels of proviral HIV DNA and CD4+ T cell activation during antiretroviral treatment. J Virol. 2014 Jul; 88(14):7818-27. PMID: 24789781.
      View in: PubMed
    57. De La Cruz J, Vollbrecht T, Frohnen P, Ng HL, Daar ES, Yang OO, Lewis MJ. Ineffectual targeting of HIV-1 Nef by cytotoxic T lymphocytes in acute infection results in no functional impairment or viremia reduction. J Virol. 2014 Jul; 88(14):7881-92. PMID: 24789790.
      View in: PubMed
    58. Gupta SK, Kitch D, Tierney C, Daar ES, Sax PE, Melbourne K, Ha B, McComsey GA. Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial. Open Forum Infect Dis. 2014 Mar; 1(1):ofu003. PMID: 25734077.
      View in: PubMed
    59. Johnson DH, Venuto C, Ritchie MD, Morse GD, Daar ES, McLaren PJ, Haas DW. Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics. 2014 Apr; 24(4):195-203. PMID: 24557078.
      View in: PubMed
    60. McComsey GA, Kitch D, Sax PE, Tierney C, Jahed NC, Melbourne K, Ha B, Brown TT, Bloom A, Fedarko N, Daar ES. Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202. J Acquir Immune Defic Syndr. 2014 Feb 01; 65(2):167-74. PMID: 24121755.
      View in: PubMed
    61. Blumenthal J, Haubrich R, Jain S, Sun X, Dube M, Daar E, Milam J, Morris S. Factors associated with high transmission risk and detectable plasma HIV RNA in HIV-infected MSM on ART. Int J STD AIDS. 2014 Sep; 25(10):734-41. PMID: 24452730.
      View in: PubMed
    62. Funderburg NT, Andrade A, Chan ES, Rosenkranz SL, Lu D, Clagett B, Pilch-Cooper HA, Rodriguez B, Feinberg J, Daar E, Mellors J, Kuritzkes D, Jacobson JM, Lederman MM. Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine. PLoS One. 2013; 8(12):e83514. PMID: 24367599.
      View in: PubMed
    63. Smith KY, Tierney C, Mollan K, Venuto CS, Budhathoki C, Ma Q, Morse GD, Sax P, Katzenstein D, Godfrey C, Fischl M, Daar ES, Collier AC. Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. Clin Infect Dis. 2014 Feb; 58(4):555-63. PMID: 24253247.
      View in: PubMed
    64. Hua L, Andersen JW, Daar ES, Glesby MJ, Hollabaugh K, Tierney C. Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment. AIDS. 2013 Nov 13; 27(17):2725-34. PMID: 23921611.
      View in: PubMed
    65. Grant PM, Tierney C, Budhathoki C, Daar ES, Sax PE, Collier AC, Fischl MA, Zolopa AR, Balamane M, Katzenstein D. Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202. HIV Clin Trials. 2013 Nov-Dec; 14(6):284-91. PMID: 24334181.
      View in: PubMed
    66. Erlandson KM, Kitch D, Tierney C, Sax PE, Daar ES, Tebas P, Melbourne K, Ha B, Jahed NC, McComsey GA. Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density. AIDS. 2013 Aug 24; 27(13):2069-79. PMID: 24384588.
      View in: PubMed
    67. Gianella S, Morris SR, Tatro E, Vargas MV, Haubrich RH, Daar ES, Dube MP, Richman DD, Little SJ, Smith DM. Virologic correlates of anti-CMV IgG levels in HIV-1-infected men. J Infect Dis. 2014 Feb 01; 209(3):452-6. PMID: 23964106.
      View in: PubMed
    68. Sloan EA, Kearney MF, Gray LR, Anastos K, Daar ES, Margolick J, Maldarelli F, Hammarskjold ML, Rekosh D. Limited nucleotide changes in the Rev response element (RRE) during HIV-1 infection alter overall Rev-RRE activity and Rev multimerization. J Virol. 2013 Oct; 87(20):11173-86. PMID: 23926352.
      View in: PubMed
    69. Hua X, Boyle CP, Harezlak J, Tate DF, Yiannoutsos CT, Cohen R, Schifitto G, Gongvatana A, Zhong J, Zhu T, Taylor MJ, Campbell TB, Daar ES, Alger JR, Singer E, Buchthal S, Toga AW, Navia B, Thompson PM. Disrupted cerebral metabolite levels and lower nadir CD4 + counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatment. Neuroimage Clin. 2013; 3:132-42. PMID: 24179857.
      View in: PubMed
    70. Andrade A, Rosenkranz SL, Cillo AR, Lu D, Daar ES, Jacobson JM, Lederman M, Acosta EP, Campbell T, Feinberg J, Flexner C, Mellors JW, Kuritzkes DR. Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J Infect Dis. 2013 Sep; 208(6):884-91. PMID: 23801609.
      View in: PubMed
    71. Gongvatana A, Harezlak J, Buchthal S, Daar E, Schifitto G, Campbell T, Taylor M, Singer E, Algers J, Zhong J, Brown M, McMahon D, So YT, Mi D, Heaton R, Robertson K, Yiannoutsos C, Cohen RA, Navia B. Progressive cerebral injury in the setting of chronic HIV infection and antiretroviral therapy. J Neurovirol. 2013 Jun; 19(3):209-18. PMID: 23613008.
      View in: PubMed
    72. Gianella S, Smith DM, Vargas MV, Little SJ, Richman DD, Daar ES, Dube MP, Zhang F, Ginocchio CC, Haubrich RH, Morris SR. Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men. Clin Infect Dis. 2013 Aug; 57(3):441-7. PMID: 23595831.
      View in: PubMed
    73. Schackman BR, Haas DW, Becker JE, Berkowitz BK, Sax PE, Daar ES, Ribaudo HJ, Freedberg KA. Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease. Antivir Ther. 2013; 18(3):399-408. PMID: 23264445.
      View in: PubMed
    74. Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet Genomics. 2012 Dec; 22(12):858-67. PMID: 23080225.
      View in: PubMed
    75. McComsey GA, Daar ES, O'Riordan M, Collier AC, Kosmiski L, Santana JL, Fichtenbaum CJ, Fink H, Sax PE, Libutti DE, Gerschenson M. Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202. J Infect Dis. 2013 Feb 15; 207(4):604-11. PMID: 23204164.
      View in: PubMed
    76. Mollan K, Daar ES, Sax PE, Balamane M, Collier AC, Fischl MA, Lalama CM, Bosch RJ, Tierney C, Katzenstein D. HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. J Infect Dis. 2012 Dec 15; 206(12):1920-30. PMID: 23148287.
      View in: PubMed
    77. Ribaudo HJ, Daar ES, Tierney C, Morse GD, Mollan K, Sax PE, Fischl MA, Collier AC, Haas DW. Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202. J Infect Dis. 2013 Feb 01; 207(3):420-5. PMID: 23148286.
      View in: PubMed
    78. Tenckhoff S, Kaiser T, Bredeek F, Donfield S, Menius E, Lail A, Mössner J, Daar ES, Tillmann HL. Role of GB virus C in HIV-1-infected and hepatitis C virus-infected hemophiliac children and adolescents. J Acquir Immune Defic Syndr. 2012 Oct 01; 61(2):243-8. PMID: 23007118.
      View in: PubMed
    79. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Melbourne K, Ha B, Brown TT, Bloom A, Fedarko N, Sax PE. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS. 2012 Jul 17; 26(11):1371-85. PMID: 22546988.
      View in: PubMed
    80. Hogan CM, Degruttola V, Sun X, Fiscus SA, Del Rio C, Hare CB, Markowitz M, Connick E, Macatangay B, Tashima KT, Kallungal B, Camp R, Morton T, Daar ES, Little S. The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis. 2012 Jan 01; 205(1):87-96. PMID: 22180621.
      View in: PubMed
    81. Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Feinberg J, Tashima K, Murphy RL, Fischl MA. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011 Oct 15; 204(8):1191-201. PMID: 21917892.
      View in: PubMed
    82. Wohl AR, Carlos JA, Tejero J, Dierst-Davies R, Daar ES, Khanlou H, Cadden J, Towner W, Frye D. Barriers and unmet need for supportive services for HIV patients in care in Los Angeles County, California. AIDS Patient Care STDS. 2011 Sep; 25(9):525-32. PMID: 21774689.
      View in: PubMed
    83. McComsey GA, Kitch D, Sax PE, Tebas P, Tierney C, Jahed NC, Myers L, Melbourne K, Ha B, Daar ES. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis. 2011 Jul 15; 53(2):185-96. PMID: 21690627.
      View in: PubMed
    84. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, Myers L, Melbourne K, Ha B, Sax PE. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011 Jun 15; 203(12):1791-801. PMID: 21606537.
      View in: PubMed
    85. Tate DF, Sampat M, Harezlak J, Fiecas M, Hogan J, Dewey J, McCaffrey D, Branson D, Russell T, Conley J, Taylor M, Schifitto G, Schifitto G, Zhong J, Daar ES, Alger J, Brown M, Singer E, Campbell T, McMahon D, Tso Y, Matesan J, Letendre S, Paulose S, Gaugh M, Tripoli C, Yiannoutsos C, Bigler ED, Cohen RA, Guttmann CR, Navia B. Regional areas and widths of the midsagittal corpus callosum among HIV-infected patients on stable antiretroviral therapies. J Neurovirol. 2011 Aug; 17(4):368-79. PMID: 21556960.
      View in: PubMed
    86. Harezlak J, Buchthal S, Taylor M, Schifitto G, Zhong J, Daar E, Alger J, Singer E, Campbell T, Yiannoutsos C, Cohen R, Navia B. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS. 2011 Mar 13; 25(5):625-33. PMID: 21297425.
      View in: PubMed
    87. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Pappa KA, Woodward WC, Patterson K, Bolivar H, Benson CA, Collier AC. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011 Apr 05; 154(7):445-56. PMID: 21320923.
      View in: PubMed
    88. Gorbach PM, Weiss RE, Jeffries R, Javanbakht M, Drumright LN, Daar ES, Little SJ. Behaviors of recently HIV-infected men who have sex with men in the year postdiagnosis: effects of drug use and partner types. J Acquir Immune Defic Syndr. 2011 Feb 01; 56(2):176-82. PMID: 21119524.
      View in: PubMed
    89. Meditz AL, MaWhinney S, Allshouse A, Feser W, Markowitz M, Little S, Hecht R, Daar ES, Collier AC, Margolick J, Kilby JM, Routy JP, Conway B, Kaldor J, Levy J, Schooley R, Cooper DA, Altfeld M, Richman D, Connick E. Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis. 2011 Feb 15; 203(4):442-51. PMID: 21245157.
      View in: PubMed
    90. Yang OO, Daar ES, Ng HL, Shih R, Jamieson BD. Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia. AIDS Res Hum Retroviruses. 2011 Apr; 27(4):391-8. PMID: 21087140.
      View in: PubMed
    91. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, O'Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, Altfeld M, Henn MR, Le Gall S, Streeck H, Haas DW, Kuritzkes DR, Robbins GK, Shafer RW, Gulick RM, Shikuma CM, Haubrich R, Riddler S, Sax PE, Daar ES, Ribaudo HJ, Agan B, Agarwal S, Ahern RL, Allen BL, Altidor S, Altschuler EL, Ambardar S, Anastos K, Anderson B, Anderson V, Andrady U, Antoniskis D, Bangsberg D, Barbaro D, Barrie W, Bartczak J, Barton S, Basden P, Basgoz N, Bazner S, Bellos NC, Benson AM, Berger J, Bernard NF, Bernard AM, Birch C, Bodner SJ, Bolan RK, Boudreaux ET, Bradley M, Braun JF, Brndjar JE, Brown SJ, Brown K, Brown ST, Burack J, Bush LM, Cafaro V, Campbell O, Campbell J, Carlson RH, Carmichael JK, Casey KK, Cavacuiti C, Celestin G, Chambers ST, Chez N, Chirch LM, Cimoch PJ, Cohen D, Cohn LE, Conway B, Cooper DA, Cornelson B, Cox DT, Cristofano MV, Cuchural G, Czartoski JL, Dahman JM, Daly JS, Davis BT, Davis K, Davod SM, DeJesus E, Dietz CA, Dunham E, Dunn ME, Ellerin TB, Eron JJ, Fangman JJ, Farel CE, Ferlazzo H, Fidler S, Fleenor-Ford A, Frankel R, Freedberg KA, French NK, Fuchs JD, Fuller JD, Gaberman J, Gallant JE, Gandhi RT, Garcia E, Garmon D, Gathe JC, Gaultier CR, Gebre W, Gilman FD, Gilson I, Goepfert PA, Gottlieb MS, Goulston C, Groger RK, Gurley TD, Haber S, Hardwicke R, Hardy WD, Harrigan PR, Hawkins TN, Heath S, Hecht FM, Henry WK, Hladek M, Hoffman RP, Horton JM, Hsu RK, Huhn GD, Hunt P, Hupert MJ, Illeman ML, Jaeger H, Jellinger RM, John M, Johnson JA, Johnson KL, Johnson H, Johnson K, Joly J, Jordan WC, Kauffman CA, Khanlou H, Killian RK, Kim AY, Kim DD, Kinder CA, Kirchner JT, Kogelman L, Kojic EM, Korthuis PT, Kurisu W, Kwon DS, LaMar M, Lampiris H, Lanzafame M, Lederman MM, Lee DM, Lee JM, Lee MJ, Lee ET, Lemoine J, Levy JA, Llibre JM, Liguori MA, Little SJ, Liu AY, Lopez AJ, Loutfy MR, Loy D, Mohammed DY, Man A, Mansour MK, Marconi VC, Markowitz M, Marques R, Martin JN, Martin HL, Mayer KH, McElrath MJ, McGhee TA, McGovern BH, McGowan K, McIntyre D, Mcleod GX, Menezes P, Mesa G, Metroka CE, Meyer-Olson D, Miller AO, Montgomery K, Mounzer KC, Nagami EH, Nagin I, Nahass RG, Nelson MO, Nielsen C, Norene DL, O'Connor DH, Ojikutu BO, Okulicz J, Oladehin OO, Oldfield EC, Olender SA, Ostrowski M, Owen WF, Pae E, Parsonnet J, Pavlatos AM, Perlmutter AM, Pierce MN, Pincus JM, Pisani L, Price LJ, Proia L, Prokesch RC, Pujet HC, Ramgopal M, Rathod A, Rausch M, Ravishankar J, Rhame FS, Richards CS, Richman DD, Rodes B, Rodriguez M, Rose RC, Rosenberg ES, Rosenthal D, Ross PE, Rubin DS, Rumbaugh E, Saenz L, Salvaggio MR, Sanchez WC, Sanjana VM, Santiago S, Schmidt W, Schuitemaker H, Sestak PM, Shalit P, Shay W, Shirvani VN, Silebi VI, Sizemore JM, Skolnik PR, Sokol-Anderson M, Sosman JM, Stabile P, Stapleton JT, Starrett S, Stein F, Stellbrink HJ, Sterman FL, Stone VE, Stone DR, Tambussi G, Taplitz RA, Tedaldi EM, Telenti A, Theisen W, Torres R, Tosiello L, Tremblay C, Tribble MA, Trinh PD, Tsao A, Ueda P, Vaccaro A, Valadas E, Vanig TJ, Vecino I, Vega VM, Veikley W, Wade BH, Walworth C, Wanidworanun C, Ward DJ, Warner DA, Weber RD, Webster D, Weis S, Wheeler DA, White DJ, Wilkins E, Winston A, Wlodaver CG, van't Wout A, Wright DP, Yang OO, Yurdin DL, Zabukovic BW, Zachary KC, Zeeman B, Zhao M. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010 Dec 10; 330(6010):1551-7. PMID: 21051598.
      View in: PubMed
    92. Miura T, Brumme ZL, Brockman MA, Rosato P, Sela J, Brumme CJ, Pereyra F, Kaufmann DE, Trocha A, Block BL, Daar ES, Connick E, Jessen H, Kelleher AD, Rosenberg E, Markowitz M, Schafer K, Vaida F, Iwamoto A, Little S, Walker BD. Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol. 2010 Aug; 84(15):7581-91. PMID: 20504921.
      View in: PubMed
    93. Para MF, Schouten J, Rosenkranz SL, Yu S, Weiner D, Tebas P, White CJ, Reeds D, Lertora J, Patterson KB, Daar ES, Cavert W, Brizz B. Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200. J Acquir Immune Defic Syndr. 2010 Apr 01; 53(4):491-5. PMID: 20130470.
      View in: PubMed
    94. Goicoechea M, Jain S, Bi L, Kemper C, Daar ES, Diamond C, Ha B, Flaherty J, Sun S, Richman D, Louie S, Haubrich R. Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients. AIDS. 2010 Mar 13; 24(5):707-16. PMID: 20087154.
      View in: PubMed
    95. Cohen RA, Harezlak J, Schifitto G, Hana G, Clark U, Gongvatana A, Paul R, Taylor M, Thompson P, Alger J, Brown M, Zhong J, Campbell T, Singer E, Daar E, McMahon D, Tso Y, Yiannoutsos CT, Navia B. Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era. J Neurovirol. 2010 Feb; 16(1):25-32. PMID: 20113183.
      View in: PubMed
    96. Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009 Dec 03; 361(23):2230-40. PMID: 19952143.
      View in: PubMed
    97. Kim HH, Daar ES. Newer antiretroviral agents and how to use them. Curr Infect Dis Rep. 2009 Jul; 11(4):327-34. PMID: 19545503.
      View in: PubMed
    98. Daar ES. Cardiovascular, renal and liver events associated with human immunodeficiency virus type 1 infection and antiretroviral therapy. F1000 Med Rep. 2009 May 28; 1. PMID: 20948738.
      View in: PubMed
    99. Kim HH, Daar ES. Newer antiretroviral agents and how to use them. Curr HIV/AIDS Rep. 2009 May; 6(2):55-62. PMID: 19358775.
      View in: PubMed
    100. Yukl S, Pillai S, Li P, Chang K, Pasutti W, Ahlgren C, Havlir D, Strain M, Günthard H, Richman D, Rice AP, Daar E, Little S, Wong JK. Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity. Virology. 2009 Apr 25; 387(1):98-108. PMID: 19268337.
      View in: PubMed
    101. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Reyor LL, Kleyman M, McMahon CM, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehrsen M, Kodira C, Roberts AD, Lauer GM, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Kim AY, Xing Y, Schneidewind A, Madey MA, Fleckenstein JF, Park VM, Galagan JE, Nusbaum C, Walker BD, Lake-Bakaar GV, Daar ES, Jacobson IM, Gomperts ED, Edlin BR, Donfield SM, Chung RT, Talal AH, Marion T, Birren BW, Henn MR, Allen TM. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology. 2008 Dec; 48(6):1769-78. PMID: 19026009.
      View in: PubMed
    102. Rieg G, Lewis RJ, Miller LG, Witt MD, Guerrero M, Daar ES. Asymptomatic sexually transmitted infections in HIV-infected men who have sex with men: prevalence, incidence, predictors, and screening strategies. AIDS Patient Care STDS. 2008 Dec; 22(12):947-54. PMID: 19072101.
      View in: PubMed
    103. Daar ES. Emerging resistance profiles of newly approved antiretroviral drugs. Top HIV Med. 2008 Oct-Nov; 16(4):110-6. PMID: 18838744.
      View in: PubMed
    104. Liu L, May S, Richman DD, Hecht FM, Markowitz M, Daar ES, Routy JP, Margolick JB, Collier AC, Woelk CH, Little SJ, Smith DM. Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance. AIDS. 2008 Apr 23; 22(7):835-9. PMID: 18427201.
      View in: PubMed
    105. Gorbach PM, Drumright LN, Javanbakht M, Pond SL, Woelk CH, Daar ES, Little SJ. Antiretroviral drug resistance and risk behavior among recently HIV-infected men who have sex with men. J Acquir Immune Defic Syndr. 2008 Apr 15; 47(5):639-43. PMID: 18285715.
      View in: PubMed
    106. Lagnese M, Daar ES. Antiretroviral regimens for treatment-experienced patients with HIV-1 infection. Expert Opin Pharmacother. 2008 Apr; 9(5):687-700. PMID: 18345948.
      View in: PubMed
    107. Balamurugan A, Lewis MJ, Kitchen CM, Robertson MN, Shiver JW, Daar ES, Pitt J, Ali A, Ng HL, Currier JS, Yang OO. Primary human immunodeficiency virus type 1 (HIV-1) infection during HIV-1 Gag vaccination. J Virol. 2008 Mar; 82(6):2784-91. PMID: 18199650.
      View in: PubMed
    108. Daar ES, Pilcher CD, Hecht FM. Clinical presentation and diagnosis of primary HIV-1 infection. Curr Opin HIV AIDS. 2008 Jan; 3(1):10-5. PMID: 19372938.
      View in: PubMed
    109. Best BM, Goicoechea M, Witt MD, Miller L, Daar ES, Diamond C, Tilles JG, Kemper CA, Larsen R, Holland DT, Sun S, Jain S, Wagner G, Capparelli EV, McCutchan JA, Haubrich RH. A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients. J Acquir Immune Defic Syndr. 2007 Dec 01; 46(4):433-42. PMID: 17786128.
      View in: PubMed
    110. Rieg G, Yeaman M, Lail AE, Donfield SM, Gomperts ED, Daar ES. Platelet count is associated with plasma HIV type 1 RNA and disease progression. AIDS Res Hum Retroviruses. 2007 Oct; 23(10):1257-61. PMID: 17961113.
      View in: PubMed
    111. Daar ES. Incorporating novel virologic tests into clinical practice. Top HIV Med. 2007 Aug-Sep; 15(4):126-9. PMID: 17720997.
      View in: PubMed
    112. Daar ES, Kesler KL, Petropoulos CJ, Huang W, Bates M, Lail AE, Coakley EP, Gomperts ED, Donfield SM. Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis. 2007 Sep 01; 45(5):643-9. PMID: 17683002.
      View in: PubMed
    113. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Miller LG, Daar ES, Gjertson DW, Kopple JD, Greenland S. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol. 2007 May; 18(5):1584-93. PMID: 17429053.
      View in: PubMed
    114. Daar ES. New approaches and resolve may define the future of the global HIV pandemic. Res Initiat Treat Action. 2007; 12(2):8-10. PMID: 17486706.
      View in: PubMed
    115. Taylor MM, Rotblatt H, Brooks JT, Montoya J, Aynalem G, Smith L, Kenney K, Laubacher L, Bustamante T, Kim-Farley R, Fielding J, Bernard B, Daar E, Kerndt PR. Epidemiologic investigation of a cluster of workplace HIV infections in the adult film industry: Los Angeles, California, 2004. Clin Infect Dis. 2007 Jan 15; 44(2):301-5. PMID: 17173235.
      View in: PubMed
    116. Daar ES. Measuring below the bar: what is it telling us? AIDS. 2006 Nov 28; 20(18):2385-7. PMID: 17117026.
      View in: PubMed
    117. Reed C, Daar ES. Novel antiretroviral agents in HIV therapy. Curr Infect Dis Rep. 2006 Nov; 8(6):489-96. PMID: 17064643.
      View in: PubMed
    118. Barbour JD, Hecht FM, Little SJ, Markowitz M, Daar ES, Kelleher AD, Routy JP, Campbell TB, Rosenberg ES, Segal MR, Weidler J, Grant RM. Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity. AIDS. 2006 Oct 24; 20(16):2123-5. PMID: 17053362.
      View in: PubMed
    119. Smith DM, Strain MC, Frost SD, Pillai SK, Wong JK, Wrin T, Liu Y, Petropolous CJ, Daar ES, Little SJ, Richman DD. Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology. 2006 Nov 10; 355(1):1-5. PMID: 16962152.
      View in: PubMed
    120. Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, Kilby JM, Daar E, Conway B, Holte S. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis. 2006 Sep 15; 194(6):725-33. PMID: 16941337.
      View in: PubMed
    121. Wagner GJ, Kanouse DE, Golinelli D, Miller LG, Daar ES, Witt MD, Diamond C, Tilles JG, Kemper CA, Larsen R, Goicoechea M, Haubrich RH. Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578). AIDS. 2006 Jun 12; 20(9):1295-302. PMID: 16816559.
      View in: PubMed
    122. Gorbach PM, Drumright LN, Daar ES, Little SJ. Transmission behaviors of recently HIV-infected men who have sex with men. J Acquir Immune Defic Syndr. 2006 May; 42(1):80-5. PMID: 16763494.
      View in: PubMed
    123. Brooks JT, Robbins KE, Youngpairoj AS, Rotblatt H, Kerndt PR, Taylor MM, Daar ES, Kalish ML. Molecular analysis of HIV strains from a cluster of worker infections in the adult film industry, Los Angeles 2004. AIDS. 2006 Apr 04; 20(6):923-8. PMID: 16549978.
      View in: PubMed
    124. Daar ES, Daar JF. Human immunodeficiency virus and fertility care: embarking on a path of knowledge and access. Fertil Steril. 2006 Feb; 85(2):298-300; discussion 301. PMID: 16595202.
      View in: PubMed
    125. Daar ES, Lynn HS, Donfield SM, Lail A, O'Brien SJ, Huang W, Winkler CA. Stromal cell-derived factor-1 genotype, coreceptor tropism, and HIV type 1 disease progression. J Infect Dis. 2005 Nov 01; 192(9):1597-605. PMID: 16206074.
      View in: PubMed
    126. Kalantar-Zadeh K, Miller LG, Daar ES. Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. Am J Kidney Dis. 2005 Aug; 46(2):290-300. PMID: 16112048.
      View in: PubMed
    127. Harcourt GC, Donfield S, Gomperts E, Daar ES, Goulder P, Phillips RE, Klenerman P. Longitudinal analysis of CD8 T-cell responses to HIV and hepatitis C virus in a cohort of co-infected haemophiliacs. AIDS. 2005 Jul 22; 19(11):1135-43. PMID: 15990566.
      View in: PubMed
    128. Daar ES, Kesler KL, Wrin T, Petropoulo CJ, Bates M, Lail A, Hellmann NS, Gomperts E, Donfield S. HIV-1 pol replication capacity predicts disease progression. AIDS. 2005 Jun 10; 19(9):871-7. PMID: 15905667.
      View in: PubMed
    129. Soogoor M, Daar ES. Primary human immunodeficiency virus type 1 infection. Curr HIV/AIDS Rep. 2005 Jun; 2(2):55-60. PMID: 16091249.
      View in: PubMed
    130. Daar ES, Richman DD. Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. AIDS Res Hum Retroviruses. 2005 May; 21(5):343-57. PMID: 15929696.
      View in: PubMed
    131. Tapper ML, Daar ES, Piliero PJ, Smith K, Steinhart C. Strategies for initiating combination antiretroviral therapy. AIDS Patient Care STDS. 2005 Apr; 19(4):224-38. PMID: 15857194.
      View in: PubMed
    132. Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, Lam RY, Daly OA, Nguyen J, Ignacio CC, Spina CA, Richman DD, Wong JK. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis. 2005 May 01; 191(9):1410-8. PMID: 15809898.
      View in: PubMed
    133. Soogoor M, Daar ES. Primary HIV-1 Infection: Diagnosis, Pathogenesis, and Treatment. Curr Infect Dis Rep. 2005 Mar; 7(2):147-153. PMID: 15727743.
      View in: PubMed
    134. Yang OO, Daar ES, Jamieson BD, Balamurugan A, Smith DM, Pitt JA, Petropoulos CJ, Richman DD, Little SJ, Brown AJ. Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strains. J Virol. 2005 Jan; 79(2):860-8. PMID: 15613314.
      View in: PubMed
    135. Yoo TW, Donfield S, Lail A, Lynn HS, Daar ES. Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. J Infect Dis. 2005 Jan 01; 191(1):4-10. PMID: 15592996.
      View in: PubMed
    136. Smith DM, Wong JK, Hightower GK, Ignacio CC, Koelsch KK, Daar ES, Richman DD, Little SJ. Incidence of HIV superinfection following primary infection. JAMA. 2004 Sep 08; 292(10):1177-8. PMID: 15353529.
      View in: PubMed
    137. Ruane PJ, Daar ES. What's next? Treatment options when the first antiretroviral regimen fails virologically or is not tolerated, Part 2. AIDS Read. 2004 Sep; 14(9):487-98. PMID: 15457602.
      View in: PubMed
    138. Ruane PJ, Daar ES. What's next? Treatment options when the first antiretroviral regimen fails virologically or is not tolerated, Part 1. AIDS Read. 2004 Aug; 14(8):421-6, 431-2, 434. PMID: 15338522.
      View in: PubMed
    139. Sagar M, Kirkegaard E, Long EM, Celum C, Buchbinder S, Daar ES, Overbaugh J. Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes. J Virol. 2004 Jul; 78(13):7279-83. PMID: 15194805.
      View in: PubMed
    140. Daar ES, Elion R. Antiretroviral rounds. Putting resistance to work. AIDS Clin Care. 2004 Jul; 16(7):56, 60. PMID: 15300926.
      View in: PubMed
    141. Wainberg MA, Brenner BG, Daar E, Gertner JM, Olivier C, Kenley S. Lack of effect of recombinant human growth hormone on the in vitro activities of antiretroviral drugs against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004 Jun; 48(6):2337-40. PMID: 15155249.
      View in: PubMed
    142. Moyle GJ, Daar ES, Gertner JM, Kotler DP, Melchior JC, O'brien F, Svanberg E. Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2004 Apr 01; 35(4):367-75. PMID: 15097153.
      View in: PubMed
    143. Leigh Brown AJ, Frost SD, Good B, Daar ES, Simon V, Markowitz M, Collier AC, Connick E, Conway B, Margolick JB, Routy JP, Corbeil J, Hellmann NS, Richman DD, Little SJ. Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection. J Virol. 2004 Mar; 78(5):2242-6. PMID: 14963120.
      View in: PubMed
    144. Daar ES. Potency and durability of antiretroviral therapy. J Acquir Immune Defic Syndr. 2003 Oct 01; 34 Suppl 2:S111-7. PMID: 14703939.
      View in: PubMed
    145. Daar ES. Antiretroviral resistance in clinical practice. J Int Assoc Physicians AIDS Care (Chic). 2003 Sep; 2 Suppl 1:S4-18. PMID: 14569655.
      View in: PubMed
    146. Henry K, Daar ES. Antiretroviral rounds. The when, why and how of switching. AIDS Clin Care. 2003 Jun; 15(6):58-9. PMID: 12866482.
      View in: PubMed
    147. Matetzky S, Domingo M, Kar S, Noc M, Shah PK, Kaul S, Daar E, Cercek B. Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med. 2003 Feb 24; 163(4):457-60. PMID: 12588205.
      View in: PubMed
    148. Daar ES, Cohen C, Remien R, Sherer R, Smith K. Improving adherence to antiretroviral therapy. AIDS Read. 2003 Feb; 13(2):81-2, 85-6, 88-90. PMID: 12645492.
      View in: PubMed
    149. Leigh Brown AJ, Frost SD, Mathews WC, Dawson K, Hellmann NS, Daar ES, Richman DD, Little SJ. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis. 2003 Feb 15; 187(4):683-6. PMID: 12599087.
      View in: PubMed
    150. Daar ES. Treatment of primary HIV infection. MedGenMed. 2002 Nov 15; 4(4):15. PMID: 12817211.
      View in: PubMed
    151. Takeuchi H, Suzuki Y, Tatsumi M, Hoshino H, Daar ES, Koyanagi Y. Isolation and characterization of an infectious HIV type 1 molecular clone from a patient with primary infection. AIDS Res Hum Retroviruses. 2002 Oct 10; 18(15):1127-33. PMID: 12402946.
      View in: PubMed
    152. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002 Aug 08; 347(6):385-94. PMID: 12167680.
      View in: PubMed
    153. Currier J, Carpenter C, Daar E, Kotler D, Wanke C. Identifying and managing morphologic complications of HIV and HAART. AIDS Read. 2002 Mar; 12(3):114-9, 124-5. PMID: 11966241.
      View in: PubMed